Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deep Chatterjee

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Plos Biology|February 22, 2022
LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domainsJui-Hung Weng, Phillip C Aoto, Robin Lorenz, et al.
Biorxiv : the Preprint Server for Biology|November 18, 2024
Type-II kinase inhibitors that target Parkinson's Disease-associated LRRK2Nicolai D Raig, Katherine J Surridge, Marta Sanz-Murillo, et al.
Molecular Cell|July 4, 2020
Structural Insights into Pseudokinase Domains of Receptor Tyrosine KinasesJoshua B Sheetz, Sebastian Mathea, Hanna Karvonen, et al.
Journal of Medicinal Chemistry|May 24, 2022
Illuminating the Dark: Highly Selective Inhibition of Serine/Threonine Kinase 17A with Pyrazolo[1,5-<i>a</i>]pyrimidine-Based MacrocyclesChristian G Kurz, Franziska Preuss, Amelie Tjaden, et al.
Science Advances|June 4, 2025
Type II kinase inhibitors that target Parkinson's disease-associated LRRK2Nicolai D Raig, Katherine J Surridge, Marta Sanz-Murillo, et al.
Plos Biology|February 3, 2025
Correction: LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domainsJui-Hung Weng, Phillip C Aoto, Robin Lorenz, et al.
Journal of Medicinal Chemistry|September 10, 2021
Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical ProbeSandra Röhm, Benedict-Tilman Berger, Martin Schröder, et al.
The Biochemical Journal|January 18, 2021
Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanismsAsad U Malik, Athanasios Karapetsas, Raja S Nirujogi, et al.
The Journal of Biological Chemistry|June 14, 2024
A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2Verena Dederer, Marta Sanz Murillo, Eva P Karasmanis, et al.
European Journal of Medicinal Chemistry|April 26, 2024
Tetrahydropyridine LIMK inhibitors: Structure activity studies and biological characterizationAnthony Champiré, Rayan Berabez, Abdennour Braka, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Plos Biology|February 22, 2022
LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domainsJui-Hung Weng, Phillip C Aoto, Robin Lorenz, et al.
Biorxiv : the Preprint Server for Biology|November 18, 2024
Type-II kinase inhibitors that target Parkinson's Disease-associated LRRK2Nicolai D Raig, Katherine J Surridge, Marta Sanz-Murillo, et al.
Molecular Cell|July 4, 2020
Structural Insights into Pseudokinase Domains of Receptor Tyrosine KinasesJoshua B Sheetz, Sebastian Mathea, Hanna Karvonen, et al.
Journal of Medicinal Chemistry|May 24, 2022
Illuminating the Dark: Highly Selective Inhibition of Serine/Threonine Kinase 17A with Pyrazolo[1,5-<i>a</i>]pyrimidine-Based MacrocyclesChristian G Kurz, Franziska Preuss, Amelie Tjaden, et al.
Science Advances|June 4, 2025
Type II kinase inhibitors that target Parkinson's disease-associated LRRK2Nicolai D Raig, Katherine J Surridge, Marta Sanz-Murillo, et al.
Plos Biology|February 3, 2025
Correction: LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domainsJui-Hung Weng, Phillip C Aoto, Robin Lorenz, et al.
Journal of Medicinal Chemistry|September 10, 2021
Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical ProbeSandra Röhm, Benedict-Tilman Berger, Martin Schröder, et al.
The Biochemical Journal|January 18, 2021
Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanismsAsad U Malik, Athanasios Karapetsas, Raja S Nirujogi, et al.
The Journal of Biological Chemistry|June 14, 2024
A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2Verena Dederer, Marta Sanz Murillo, Eva P Karasmanis, et al.
European Journal of Medicinal Chemistry|April 26, 2024
Tetrahydropyridine LIMK inhibitors: Structure activity studies and biological characterizationAnthony Champiré, Rayan Berabez, Abdennour Braka, et al.
Pageof 4